Symbols

SGMT

Sagimet Biosciences·NASDAQ

--(--)

SGMT Profile

Sagimet Biosciences Inc.

A clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN)

Industry

Pharmaceutical

Established Date

12/19/2006

Listing Date

07/14/2023

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.sagimet.com

Security Type

Common stock

Office address

155 Bovet Road, Suite 303, San Mateo, California 94402

Business

Introduction

Sagimet Biosciences Inc., was incorporated in Delaware on December 19, 2006. The company is a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors for the metabolic and fibrotic pathways. Its lead drug candidate, denifanstat, is an oral selective FASN inhibitor that is being developed for the treatment of metabolic dysfunction-associated steatohepatitis, acne and certain cancers.